{
    "clinical_study": {
        "@rank": "109337", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 JTZ-951 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose per day for 15 days"
            }, 
            {
                "arm_group_label": "Dose 2 JTZ-951 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose per day for 15 days"
            }, 
            {
                "arm_group_label": "Dose 3 JTZ-951 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose per day for 15 days"
            }, 
            {
                "arm_group_label": "Dose 4 JTZ-951 or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose per day for 15 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK),\n      and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days\n      in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis."
        }, 
        "brief_title": "Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia of Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have ESRD and have been receiving maintenance hemodialysis for at least\n             12 weeks prior to the Screening Visit\n\n          -  Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between\n             20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit\n\n          -  Hemoglobin value as defined in the protocol\n\n          -  Meet the erythropoiesis-stimulating agent (ESA) therapy criteria at the Screening\n             Visit as defined in the protocol\n\n        Exclusion Criteria:\n\n          -  Transferrin saturation and ferritin levels at the Screening Visit as defined in the\n             protocol\n\n          -  Anemia due to known causes other than chronic kidney disease\n\n          -  Known history of hyporesponsiveness to ESAs\n\n          -  Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to\n             Screening visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971164", 
            "org_study_id": "AZ951-U-12-004"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose 1 JTZ-951 or Placebo", 
                    "Dose 2 JTZ-951 or Placebo", 
                    "Dose 3 JTZ-951 or Placebo", 
                    "Dose 4 JTZ-951 or Placebo"
                ], 
                "description": "Subjects will receive JTZ-951 or Placebo", 
                "intervention_name": "JTZ-951", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Dose 1 JTZ-951 or Placebo", 
                    "Dose 2 JTZ-951 or Placebo", 
                    "Dose 3 JTZ-951 or Placebo", 
                    "Dose 4 JTZ-951 or Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "anemia", 
            "chronic kidney disease", 
            "hemodialysis"
        ], 
        "lastchanged_date": "March 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Paul", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease", 
        "overall_contact": {
            "email": "yamamoto@akrospharma.com", 
            "last_name": "Hideyuki Yamamoto", 
            "phone": "609-919-6111"
        }, 
        "overall_official": {
            "affiliation": "Akros Pharma Inc.", 
            "last_name": "Hideyuki Yamamoto", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Vital signs and 12 lead ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Cmax (maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "tmax (time to reach maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "t1/2 (elimination half-life)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "AUC (area under the concentration-time curve)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "AR (accumulation ratio)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "RBC (red blood cell) count", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Hgb (hemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "TSAT (transferrin saturation)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "serum ferritin", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971164"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Akros Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Akros Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}